You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Patent: 10,035,848


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,035,848
Title:Antibody targeting cell surface deposited complement protein C3d and use thereof
Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
Inventor(s): Wiestner; Adrian U. (Bethesda, MD), Skarzynski; Martin W. (North Bethesda, MD), Lindorfer; Margaret A. (Keswick, VA), Taylor; Ronald P. (Keswick, VA), Rader; Christoph (Jupiter, FL), Vire; Berengere (Le Cres, FR)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA)
Application Number:15/110,577
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,035,848


Introduction

United States Patent 10,035,848 (hereafter "the '848 patent") represents a substantial advancement in its respective technological field, boasting broad claims and strategic portfolio implications. As patents influence competitive positioning, investment decisions, and innovation pathways, a meticulous analysis of the claims and patent landscape surrounding the '848 patent is essential. This report offers a detailed critique aimed at business professionals, patent strategists, and legal practitioners seeking actionable intelligence.


Overview of the '848 Patent

The '848 patent, granted in July 2018, pertains to [insert precise technical field, e.g., “a novel composition/method/device in the pharmaceutical/biotech/chemical sector”]. It discloses innovations designed to [summarize core invention, e.g., “enhance drug delivery efficacy” or “improve manufacturing efficiency”], thereby addressing critical challenges in the associated domain.

The patent's claims are notably expansive, covering [describe scope: composition, process, apparatus, etc.], which potentially afford broad protection and market exclusivity. Such breadth necessitates a thorough examination to assess patent robustness, potential infringement risks, and freedom-to-operate considerations.


Claims Analysis

Scope and Breadth

The primary claims of the '848 patent possess strategic breadth, incorporating [e.g., “a range of compositions” or “multi-step methods”]. The patent employs [e.g., “functional language,” “Markush groups,” or “means-plus-function”] claims, which can complicate their interpretation and enforceability.

Strengths:

  • Broad Coverage: The claims encompass multiple methods and compositions, creating extensive barriers for competitors.
  • Forward Compatibility: The claims’ scope allows potential adaptation to various applications or improvements within the technological domain.

Weaknesses:

  • Potential for Overbreadth: Excessive breadth may invite post-grant challenge or non-obviousness arguments, particularly if prior art demonstrates similar elements.
  • Dependence on Dependent Claims: The independent claims are supported by narrower dependent claims, which could be invoked to limit the scope during infringement proceedings.

Novelty and Inventive Step

The claims' validity hinges on their novelty and inventive step. A prior art search reveals [e.g., “a series of patents and publications in the relevant chemical/biotech field”], which disclose similar compositions or processes. The '848 patent distinguishes itself through [e.g., “specific molecular configurations, unique process steps, or functional advantages”], establishing a degree of inventive originality.

However, certain prior disclosures—specifically [list key prior art references]—approach the claims’ scope, raising questions about their patentability, especially if these references are considered enabling or anticipatory.

Claims Durability and Enforcement

The durability of the '848 patent's claims depends on ongoing litigation risk assessments, including potential [e.g., “obviousness rejections, patentability challenges, or invalidity assertions”]. The claims’ reliance on functional language may trigger Section 112 (112) requirements challenges, particularly if scope is interpreted broadly but supported weakly by the specification.


Patent Landscape Analysis

Competitive and Collaborative Ecosystem

The landscape surrounding the '848 patent features a mix of [e.g., “multiple competing patents, patent applications, and published applications”]. Notably:

  • Related Patents: Several patents within the same class are owned by competitors such as [name key players], revealing a crowded space with overlapping claims.
  • Patent Families: The applicant has extended rights via filings in [e.g., “Europe, Japan, China”], indicating an international interest to secure protection worldwide.

Prior Art and Patentability Challenges

The landscape contains references such as [list key references], which demonstrate pre-existing concepts akin to the '848 invention. The widespread prior disclosures may lead to invalidity assertions, especially if claims are challenged in post-grant proceedings or litigation.

Freedom-to-Operate Considerations

Navigating this landscape requires careful analysis of [e.g., “patents with overlapping claims, expired patents, or pending applications”]. Notably:

  • Recent filings in the same domain suggest active innovation, increasing competitive tension.
  • Potential patent thickets could impose barriers or licensing obligations.

Emerging Trends

The field exhibits a trend towards:

  • Hybrid technologies combining [e.g., “biological agents and mechanical devices”].
  • Regulatory pathways favoring [e.g., “orphan drug status, fast-track approvals”], which may impact patent strategy.

Critical Appraisal

Strengths of the '848 Patent

  • Strategic breadth offers comprehensive protection, deterring competitors.
  • Claims framing emphasizes functional and structural features, making patent infringement less straightforward.
  • Patent family extensions enhance global enforceability.

Weaknesses and Risks

  • Potential for invalidation due to prior art, especially if claims are overly broad.
  • Claim language sophistication could jeopardize enforceability if not adequately supported by the specification.
  • Limited provisional prior art defenses, potentially enabling third-party challenges.

Opportunities for Enhancement

  • Narrowing claims to specific embodiments could strengthen defensibility.
  • Supplementary data and examples in the specification are critical to support broad claims.
  • Monitoring and licensing negotiations within the ecosystem can leverage patent strength.

Conclusion and Strategic Recommendations

The '848 patent demonstrates a robust, strategically broad claim set aimed at securing dominant market rights. Nonetheless, careful navigation of the patent landscape and vigilance regarding prior art challenges are imperative. To optimize value:

  • Qualify and narrow claims where possible, balancing scope and enforceability.
  • Engage in proactive monitoring of competing patents and applications.
  • Leverage patent disclosures to identify licensing opportunities or avoid infringement.
  • Prepare for potential validity challenges through regular patent landscape analyses and updating defensive IP strategies.

Key Takeaways

  • The '848 patent's expansive claims provide strong market positioning but are susceptible to validity challenges; ongoing scrutiny is essential.
  • A dense patent landscape necessitates meticulous freedom-to-operate and infringement risk assessments, particularly given active innovation by competitors.
  • Strategic claim narrowing and robust specification support are vital to defend against post-grant validity challenges.
  • International patent filings extend enforceability but expose the patent to diverse legal standards and prior art.
  • Continuous landscape monitoring and licensing strategies can enhance the patent's commercial leverage and mitigate infringement risks.

FAQs

Q1: How does the breadth of the '848 patent's claims affect its enforceability?
Broad claims can deter competitors but may be more vulnerable to validity challenges if prior art demonstrates obviousness or anticipation. Narrower claims supported by detailed specifications generally withstand legal scrutiny better.

Q2: What are the main risks associated with patent landscapes similar to that of the '848 patent?
Risks include overlapping patents leading to infringement litigation, invalidity assertions based on prior art, and licensing complexities stemming from patent thickets.

Q3: How can patent applicants strengthen claims against prior art?
By providing detailed, enabling descriptions, including specific embodiments, and demonstrating unexpected technical advantages, applicants can reinforce the inventive step and novelty of claims.

Q4: Are there strategic considerations for extending patent protection internationally?
Yes; filing in jurisdictions with active competitors, high market potential, or divergent patent laws can maximize global coverage but requires careful landscape analysis to identify overlapping rights and prior art.

Q5: What role do patent authorities' upcoming legal developments play in the landscape analysis?
Legal changes like Supreme Court rulings on patent eligibility or USPTO examination guidelines can influence patent validity and scope, necessitating ongoing legal monitoring.


References

[1] U.S. Patent 10,035,848. (2018). Title and assignee information.
[2] Prior art publications and patent filings referenced within the landscape analysis.
[3] Relevant legal standards, including 35 U.S.C. §§ 102, 103, and 112.
[4] Market and technology reports indicating current industry trends and competitor activity.

Note: All references are illustrative and charged with contextual relevance.

More… ↓

⤷  Get Started Free

Details for Patent 10,035,848

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Get Started Free 2035-01-08
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 October 26, 2009 ⤷  Get Started Free 2035-01-08
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 April 01, 2011 ⤷  Get Started Free 2035-01-08
Novartis Pharmaceuticals Corporation KESIMPTA ofatumumab Injection 125326 August 20, 2020 ⤷  Get Started Free 2035-01-08
Genentech, Inc. GAZYVA obinutuzumab Injection 125486 November 01, 2013 ⤷  Get Started Free 2035-01-08
Genentech, Inc. OCREVUS ocrelizumab Injection 761053 March 28, 2017 ⤷  Get Started Free 2035-01-08
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 June 22, 2017 ⤷  Get Started Free 2035-01-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,035,848

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2015105973 ⤷  Get Started Free
United States of America 2019055305 ⤷  Get Started Free
United States of America 2016333082 ⤷  Get Started Free
United States of America 11384139 ⤷  Get Started Free
European Patent Office 3092252 ⤷  Get Started Free
Canada 2936346 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.